Business Wire

CA-CONVIVA

24.8.2022 16:03:10 CEST | Business Wire | Press release

Share
Conviva’s Breakthrough Streaming Analytics Innovation Recognized With Two ACM SIGCOMM Innovation Awards

Conviva , the leading global streaming analytics platform, has been recognized by the Association for Computing Machinery’s Special Interest Group on Data Communications (ACM SIGCOMM) with two prestigious innovation awards: the ACM SIGCOMM Test of Time Award and the SIGCOMM Networking Systems Award. Both awards honor the vision and impact of Conviva’s commitment to data and analytics technology innovation that began with the founding team of Hui Zhang, Aditya Ganjam, Jibin Zhan (Conviva) and Ion Stoica (Conviva, Databricks) defining standards that pushed the industry forward. This team’s work has continued to be foundational to enabling and continuously improving the quality and overall end-user experience that is industry standard in streaming media today. This same core technology has also proven applicable to virtually any industry where technology and business leaders have a business imperative to make the vast amount of their data available to their organizations in real time, and actionable across every aspect of their operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220824005274/en/

2022 SIGCOMM Test of Time Award

The 2022 ACM SIGCOMM Test of Time Award honors Conviva’s founders for their 2011 paper detailing the direct connection between video quality and user engagement. The annual award recognizes papers published 10 to 12 years in the past that are deemed to offer data, perspective and predictions that still have significance today.

“What we didn’t predict was who would be the winners and losers of the streaming wars,” said Hui Zhang, Conviva Cofounder, Chief Scientist and Chairman of the Board. “What we did know ten years ago, and still holds true today, is that measuring quality and engagement in streaming is core to market growth and who comes out on top. Having this real-time information at their fingertips is mission-critical for publishers and brands to inform any actions to optimize their services and maximize their investment.”

The breakthrough technology that underscored the Test of Time award was documented in a paper, “Understanding the Impact of Video Quality on User Engagement” that was first presented at the 2011 ACM SIGCOMM conference. Its authors were Conviva founders Hui Zhang, Ion Stoica, Aditya Ganjam and Jibin Zhan, along with teammates Florin Dobrian, Asad Awan, Dilip Joseph and Vyas Sekar, an academic collaborator and now Professor of Carnegie Mellon University. The paper pioneered large-scale video measurements and documented an in-depth study conducted on how video quality affects user engagement, which has had a lasting impact on the optimization of streaming media.

The State of Streaming

While video streaming quality has significantly improved in the past 10 years, consumer expectations have also risen to new heights. Nothing short of high resolution and smooth playback all-the-time is acceptable. Detection and identifying root-cause of any barriers to an excellent experience is more challenging than ever due to the complexity of today’s streaming technology ecosystem. Diverse mobile-connected TV devices and associated video/app tech stacks, sophisticated cloud-based media preparation, content distribution, and advertising tech stacks all can contribute to more microscopic and subtle failure modes. More than a trillion-dollar market (ranging from media, entertainment, sports, education and fitness industries) is built on top of streaming, making it table stakes to ensure every media consumer has the best experience.

Each quarter, Conviva conducts an in-depth global review of streaming quality and adoption in a report entitled The State of Streaming.

2022 SIGCOMM Networking Systems Award

A separate SIGCOMM award committee also selected Conviva as the recipient of the 2022 SIGCOMM Networking Systems Award, recognizing the development of a networking system that has had a significant impact on the world of communications and computer networks. According to the committee, Conviva was recognized for “the sustained impact that Conviva has had, from the earliest days of translating published research to a successful real-world system, making a significant impact on real-world streaming systems and CDNs and then continuing to give back to the research community via data sharing and publications.”

“While I am very proud that Conviva has been recognized for its impact on the industry, our contribution to the research community is also very meaningful,” added Zhang. “I am thankful to all of our academic collaborators and talented undergrad and graduate interns from top research programs at CMU, Berkeley, Chicago, Purdue, and USC.”

The 2022 Test of Time winners were selected by an esteemed committee of technology experts that included Fadel Adib (MIT), Venkat Padmanabhan (Microsoft Research India, chair), Jennifer Rexford (Princeton) and Renata Teixeira (Netflix). The 2022 SIGCOMM Networking Systems Award was selected by a committee that included Vishal Misra, Anees Shaikh and Puneet Sharma.

About ACM SIGCOMM

The Association for Computing Machinery (ACM) is the world’s largest educational and scientific computing society, and SIGCOMM is ACM’s professional forum for the discussion of topics in the field of communications and computer networks, including technical design and engineering, regulation and operations, and the social implications of computer networking. The SIG's members are particularly interested in the systems engineering and architectural questions of communication.

About Conviva

Conviva helps streaming businesses act within seconds of observation to grow their business ahead of the competition. Conviva’s leading global streaming analytics platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. Using just a single sensor and a single pipeline, its 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today the Conviva platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. To learn more, visit www.conviva.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/convivainc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye